Compugen partners with BMS for Phase I combo trial of its first-in-class checkpoint inhibitor

Compugen Ltd. (NASDAQ:CGEN) partnered with Bristol-Myers Squibb Co. (NYSE:BMY) to evaluate its first-in-class mAb COM701 plus BMS's anti-PD-1 mAb Opdivo nivolumab for advanced solid tumors.

COM701 targets new checkpoint target poliovirus receptor related immunoglobulin domain containing (PVRIG; CD112R) (see "Computing Checkpoints")...